Phase II oncology trials

Two Combination Regimens Become NCCN‑Preferred First‑Line Options for EGFR‑Mutated Lung Cancer

Experts now individualize first‑line care by weighing TP53 co‑mutation, ctDNA clearance, intracranial data to choose between a chemo‑sparing antibody‑TKI or a chemo‑containing TKI regimen.